IRIS
SIMONELLI, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.534
AS - Asia 1.958
EU - Europa 1.043
SA - Sud America 672
AF - Africa 151
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 2
Totale 8.366
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.446
SG - Singapore 1.131
BR - Brasile 558
CN - Cina 373
FI - Finlandia 224
IT - Italia 193
IE - Irlanda 162
VN - Vietnam 149
NG - Nigeria 117
DE - Germania 116
FR - Francia 76
HK - Hong Kong 76
SE - Svezia 72
CA - Canada 61
GB - Regno Unito 56
NL - Olanda 51
AR - Argentina 44
IN - India 38
TR - Turchia 36
BD - Bangladesh 27
EC - Ecuador 24
IL - Israele 24
ID - Indonesia 22
BE - Belgio 16
MX - Messico 15
PL - Polonia 14
IQ - Iraq 13
JP - Giappone 13
VE - Venezuela 12
ZA - Sudafrica 11
CL - Cile 10
CO - Colombia 10
UA - Ucraina 9
ES - Italia 8
RU - Federazione Russa 8
AT - Austria 7
SA - Arabia Saudita 7
EG - Egitto 6
PK - Pakistan 6
TN - Tunisia 6
UY - Uruguay 6
MA - Marocco 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
EU - Europa 4
IR - Iran 4
LT - Lituania 4
TW - Taiwan 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
JM - Giamaica 3
LB - Libano 3
PE - Perù 3
PH - Filippine 3
PT - Portogallo 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
GE - Georgia 2
HN - Honduras 2
KE - Kenya 2
KR - Corea 2
MD - Moldavia 2
MK - Macedonia 2
MY - Malesia 2
PS - Palestinian Territory 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BY - Bielorussia 1
CR - Costa Rica 1
DM - Dominica 1
ET - Etiopia 1
HR - Croazia 1
KG - Kirghizistan 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
SI - Slovenia 1
TJ - Tagikistan 1
Totale 8.366
Salva come PNG Salva come JPEG
Città #
Wilmington 706
Chandler 508
Singapore 356
Dallas 354
San Mateo 299
The Dalles 291
Ashburn 236
Helsinki 223
Shanghai 216
Ann Arbor 189
New York 184
Dublin 162
Lawrence 127
Princeton 127
Leawood 119
Benin City 117
Milan 86
Beijing 84
Woodbridge 81
Boardman 79
Hong Kong 76
Paris 67
Phoenix 63
Fairfield 60
São Paulo 58
Ho Chi Minh City 51
Los Angeles 44
Amsterdam 42
Toronto 40
London 32
Seattle 30
Hanoi 29
Kocaeli 29
Santa Clara 23
San Diego 21
Naples 19
Rio de Janeiro 16
Brussels 15
Pune 15
Belo Horizonte 14
Council Bluffs 13
Norwalk 12
Boston 11
Chennai 11
Orem 11
Porto Alegre 11
Warsaw 11
Curitiba 9
Guayaquil 9
Tokyo 9
Abbiategrasso 8
Columbus 8
Denver 8
Monmouth Junction 8
Montreal 8
Munich 8
Stockholm 8
Brasília 7
Brooklyn 7
Haiphong 7
Mexico City 7
San Francisco 7
Atlanta 6
Biên Hòa 6
Chicago 6
Da Nang 6
Dhaka 6
Fortaleza 6
Genoa 6
Goiânia 6
Guarulhos 6
Quito 6
Buenos Aires 5
Charlotte 5
Des Moines 5
Johannesburg 5
Manchester 5
Montevideo 5
Nanjing 5
Redmond 5
Reston 5
Uberlândia 5
Aracaju 4
Baghdad 4
Betim 4
Cairo 4
Calgary 4
Düsseldorf 4
Falkenstein 4
Feira de Santana 4
Ipatinga 4
Jacksonville 4
Nova Iguaçu 4
Nuremberg 4
Poplar 4
Raleigh 4
Redwood City 4
Ribeirão Preto 4
Salvador 4
Tashkent 4
Totale 5.668
Salva come PNG Salva come JPEG
Nome #
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 111
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas 109
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 107
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 101
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 100
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 99
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 97
Treatment of malignant pleural mesothelioma: current status and future directions 96
COVID-19 and liver cancer clinical trials: not everything is lost 94
Role of Myeloid Cells in the Immunosuppressive Microenvironment in Gliomas 87
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 86
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 86
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 85
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 85
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 83
Advances in the biology of malignant pleural mesothelioma 83
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 80
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 79
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report 77
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 76
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care 76
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 75
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 74
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 74
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 74
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 72
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 72
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 72
Reproducibility of the WHO classification of thymomas: practical implications 71
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 70
Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy 69
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. 69
Infertility risk and teratogenicity of molecular targeted anticancer therapy: a challenging issue 68
HIGH-GRADE GLIOMAS AND IMMUNOTHERAPEUTIC EARLY PHASE CLINICAL TRIALS: A SINGLE-CENTER EXPERIENCE 68
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 67
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 67
Neutrophils in Gliomas 67
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 67
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series 67
Pathological characterization of nivolumab –related liver injury in a patient with glioblastoma 66
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 66
The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing 66
Herpes infections in breast cancer patients treated with adjuvant chemotherapy 65
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 65
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis 65
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 65
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in a observational study 64
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 64
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor alpha, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma 64
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 64
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 63
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience 62
Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study 62
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution 62
Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy 62
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome 61
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment 61
Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging" 60
HYPOFRACTIONATED RADIATION THERAPY (OVER 3 WEEKS) CAN REPLACE CONVENTIONAL RADIATION THERAPY SCHEDULE (OVER 6 WEEKS) IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? THE TIMES ARE RIPE 60
Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors 59
Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. 59
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 58
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 58
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) 58
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 57
Imaging biomarkers in primary brain tumours 57
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 57
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma 55
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 55
Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy 55
Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes 55
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations 54
Electrolyte abnormalities and side effects of zoledronate in patients with bone metastases 54
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 54
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 54
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal 54
Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study 53
Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study 53
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study 52
Phase II study of hypofractionated radiation therapy with concomitant and adjuvant Temozolomide following surgical resection for patients with newly diagnosed glioblastoma:preliminary evaluation 52
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 52
Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma 52
Future developments in the management of malignant pleural mesothelioma 52
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review 51
Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis 51
NaCl enhances CD8+ T cell effector functions in cancer immunotherapy 50
Outcome evaluation of patients with diagnosed WHO grade III glioma treated according to the molecular profile, the hystology, and the extent of resection (EOR) 50
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 50
Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future 50
Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs 50
High incidence of hypocalcemia in patients with bone metastases from different kinds of neoplasms, treated with zoledronate 49
Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial 49
Intensified chemotherapy with stem-cell rescue in germ-cell tumors 49
Supratotal resection in newly diagnosed GBMs: role of this surgical strategy beyond enhancing boundaries 48
Three-day low-dose Cisplatin administration in advanced non-small cell lung cancer (NSCLC): Efficacy and reduced toxicity 48
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey 48
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 48
Optimizing residual surgery for patients with primary extragonadal germ cell tumors 47
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S) 47
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report 47
Totale 6.578
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.474
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.474
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.331 0 0 0 0 0 395 184 99 281 185 17 170
2021/2022689 32 5 13 139 4 6 28 102 55 71 199 35
2022/20231.536 285 66 162 148 120 99 3 119 261 153 107 13
2023/20241.113 58 108 171 39 45 251 88 47 11 32 109 154
2024/20251.553 33 17 10 27 33 162 64 166 270 359 197 215
2025/20262.169 609 416 370 484 134 156 0 0 0 0 0 0
Totale 8.530